Abstract: Purpose/Background: Negative symptoms and cognitive impairments tend to co-occur in people with schizophrenia. If their association with each other is due, in part, to shared pathophysiology, then this suggests that a single drug could potentially be effective for both domains. The current study was designed to examine this hypothesis.
N egative symptoms and cognitive impairments tend to co-occur in people with schizophrenia. 1 However, it is not known whether the association between these 2 domains is based on shared pathophysiology or the effect each has on the assessment of the other. 2 If the association between negative symptoms and cognitive impairments is due, in part, to shared pathophysiology, then this suggests the hypothesis that a single drug could potentially be effective for both domains. However, if there is limited overlap in pathophysiology, then separate medications would be required.
In order to test this hypothesis, we selected 2 agents, for which, at the time of study initiation (2009), there was preliminary evidence for their potential efficacy for these domains. We selected intranasal oxytocin for the treatment of negative symptoms, because preclinical studies suggested that oxytocin improves social behavior, including retention of social memories, 3 duration of social contacts, 4, 5 and social affiliation in rats exposed to maternal stress (J. Koenig et al, unpublished data). In addition, singledose intranasal oxytocin transiently improves various aspects of social cognition in human control subjects. [6] [7] [8] [9] [10] [11] Finally, initial descriptive studies suggested oxytocin levels were abnormal in people with schizophrenia. 12 We selected galantamine for the treatment of cognitive impairments, because agents that modulate the α7 nicotinic receptor have been hypothesized to be effective for the treatment of cognitive impairments in people with schizophrenia. 13 In addition to its ability to inhibit acetylcholinesterase, galantamine is a positive allosteric modulator at the α4β2 and α7 nicotinic receptors. [14] [15] [16] In a previous study, we found that galantamine was effective for processing speed and verbal memory. 17 Similar results were observed in some, 18, 19 but not all, 20 other studies with galantamine. In addition, 2 studies with the α7 nicotinic receptor partial agonist, 3-[(2,4-dimethoxy)benzylidene] anabaseine (DMXB-A), suggested that α7 nicotinic receptor agents could improve cognition. 21, 22 In the current randomized clinical trial, we tested whether similar or different pathways were associated with the treatment of negative symptoms and cognitive impairments by determining the effect of intranasal oxytocin and galantamine on these 2 domains. We hypothesized that intranasal oxytocin would improve negative symptoms, and galantamine would selectively improve cognitive function in people with schizophrenia.
MATERIALS AND METHODS

Participants
Inpatients or outpatients, between 18 and 65 years old, who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia or schizoaffective disorder were selected for study entry. Participants received a diagnosis using a best estimate diagnostic approach, which utilized information from the Structured Clinical Interview for DSM-IV, 23 direct assessment, family informants, and past medical records. Participants were required to be clinically stable, in the nonacute phase of their illness, and meet retrospective and prospective criteria for persistent negative symptoms. 24, 25 The retrospective determination of persistence was based on the bestestimate diagnosis and/or therapist report. The prospective definition of persistence used negative symptom assessments completed at the beginning and end of a 4-week evaluation phase. Participants were required to demonstrate a minimum level of negative symptoms, defined as a modified Scale for the Assessment of Negative Symptoms (SANS) total score of 20 or greater or alogia global score of 3 or greater. 25 They were also required to not exceed specified levels of positive symptoms (ie, Brief Psychiatric Rating Scale [BPRS] 26 positive symptom total score ≤16), affective symptoms (ie, BPRS Anxiety/Depression factor score ≤14), and extrapyramidal symptoms (ie, Simpson-Angus Extrapyramidal Symptom Rating Scale [SAS] 27 total score ≤10). In addition, participants were required to have been on the same antipsychotic(s) for 2 months and the same dose(s) for 1 month. If prescribed other psychotropic medications, they were required to have been on the same drug and dose for at least 30 days. Participants with a DSM-IV-TR diagnosis of alcohol or substance abuse (other than nicotine) within the last month, alcohol or substance dependence (other than nicotine) within the last 6 months, or mental retardation or who had an unstable medical condition were excluded. Pregnant and lactating female participants were excluded.
The University of Maryland School of Medicine and the State of Maryland Department of Health and Mental Hygiene institutional review boards approved the study protocol and informed consent procedures. Written informed consent was obtained from all participants after study procedures had been fully explained and prior to study participation. Participant ability to provide valid informed consent was documented using study-specific procedures.
Clinical Assessments
The modified SANS total score was the primary measure used to assess negative symptom change. 25 The BPRS positive symptom item total score was used to assess positive symptom change. The 4 BPRS positive symptom items are as follows: conceptual disorganization, hallucinatory behavior, unusual thought content, and suspiciousness. The Calgary Depression Scale (CDS) 28 total score was used to assess depressive symptom change. The Clinical Global Impression (CGI) Severity of Illness item was used to assess global clinical changes. The SANS, BPRS, CDS, and CGI were obtained at the beginning and end of the Evaluation Phase and biweekly during the double-blind treatment phase. Intraclass correlation coefficients for these instruments ranged from 0.76 to 0.90. All raters were blind to treatment assignment.
Neuropsychological and Functional Capacity Assessments
The MATRICS Consensus Cognitive Battery (MCCB) and the Rapid Visual Information Processing (RVIP) test were used to assess neuropsychological test performance. The MCCB is composed of 10 tests, which assess 7 cognitive domains. 29 The MCCB composite score is a standardized mean of the 7 domain scores; t scores are standardized to normative data and have an estimated mean of 50 and SD of 10 in the general healthy population. 30 The RVIP test is a computerized measure of sustained attention, 31 which requires participants to respond when they see a target sequence of 3 odd or 3 even digits in a stream of single digits (from 1 to 9) presented at a rate of 1/600 milliseconds.
A modified version of the UCSD Performance-Based Skills Assessment (UPSA), 32 the UPSA-2, was used to assess functional capacity. In comparison to the UPSA, the UPSA-2 contains a sixth component: Medication Management, and the content complexity and number of items required to be remembered are increased for the Comprehension/Planning, Financial Skills, and Transportation components to reduce potential for ceiling effects. The MCCB, RVIP test, and UPSA-2 were administered at the end of the evaluation and double-blind phases.
Safety Assessments
A standard blood chemistry panel, complete blood count, urinalysis, and electrocardiogram were obtained in the evaluation phase and at the end of the double-blind treatment phase. Female participants of child-bearing potential had a biweekly pregnancy test. The SAS, the Abnormal Involuntary Movement Scale (AIMS), 33 and the Barnes Akathisia Scale (BAS) 34 were used to assess extrapyramidal symptoms, dyskinetic movements, and akathisia, respectively. The SAS, AIMS, and BAS were administered at the end of the evaluation and double-blind phases. The Side Effect Checklist (SEC) was used to assess adverse effects and monitor vital signs. The SEC is composed of 32 common adverse effects, which are rated on a 1-point (none) to 4-point (severe) scale. The SEC ratings were conducted at the end of the evaluation phase and weekly through the study.
Oxytocin Levels
Plasma oxytocin levels were determined via radioimmunoassay using a magnetic bead kit from Phoenix Pharmaceuticals, Inc, Burlingame, Calif. Samples were assayed in duplicate; the average of these samples was taken as the final oxytocin value. Assay sensitivity was 5 pg/mL with minimal cross reactivity with vasopressin. The coefficient of variation averaged 5% to 8% across the assays. Plasma oxytocin levels were obtained at the end of the evaluation and the double-blind phases.
Study Design
The study consisted of a 4-week evaluation phase and a 6-week double-blind treatment phase. After participants signed consent, they entered the evaluation phase, during which they underwent medical screening and baseline symptom, safety, and cognitive assessments. Participants who met inclusion criteria entered the 6-week double-blind treatment phase and were randomized to 1 of 3 treatment regimens: active intranasal oxytocin and placebo galantamine, placebo intranasal oxytocin and active galantamine, or placebo intranasal oxytocin and placebo galantamine. The intranasal oxytocin dose was 24 IU twice a day. Victoria Apotheke Zuerich (Pharmaworld.com) provided the intranasal oxytocin (Syntocinon from Novartis Pharmaceuticals, Basel, Switzerland) and matching intranasal placebo oxytocin. The intranasal oxytocin concentration was validated by the University of Maryland School of Pharmacy GMP facility. All participants were educated and received a practice intranasal saline dispenser to ensure proper use of the intranasal oxytocin. The galantamine target dose was 12 mg twice a day; the following titration schedule was used: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks. The galantamine was purchased from Value Drug Company (Duncansville, Pa) and blinded by Zonetak Pharmacy (Owings Mills, Md). Participants were assigned study treatment from a list of random assignments generated using permuted block randomizations with variable block sizes. In response to a randomization request, the biostatistician sent a code number to the unblinded pharmacist, which identified the next treatment selection to be dispensed from the treatment sequence.
If a participant could not tolerate his/her study medication, he/she was instructed to skip a dose and then resume treatment with the prescribed dose. If the participant was still unable to tolerate his/her study medication, then the dose could be lowered to alleviate adverse effects.
Medication compliance was assessed by weekly pill count and weight of returned intranasal bottles. All participants who received 75% or more of their assigned study medication were considered compliant.
Statistical Analyses
The method of Hedeker and colleagues 35 to estimate power for linear contrasts in longitudinal data with attrition was used to calculate sample size for the oxytocin versus placebo SANS total score comparison. We found that 40 participants per group would provide power = 0.80 (testing at α = 0.025 to allow for multiple primary outcomes) to detect a 6-point group difference in the SANS total score (an effect size of 0.5 SD). Prior clinical trial data were used to estimate the correlations among baseline and postrandomization SANS total scores. 25, 36 In the primary analysis, a post hoc contrast from a mixed model for repeated-measures analysis of covariance (MM-ANCOVA): follow-up SANS total score = baseline SANS total score + week + treatment + treatment Â week, where the correlation between repeated follow-up measurements was modeled using an unstructured covariance matrix, was used to test for SANS total score final study visit group differences. In this model, the treatment term estimates the average group difference (across weeks), and the treatment Â week interaction term allows post hoc group comparisons at particular weeks. SAS PROC Mixed (SAS Institute Inc, Cary, NC) was used to fit these models, using the Kenward-Rogers approximation to calculate degrees of freedom for hypothesis tests. All participants with postbaseline SANS data were included in these models, without imputation for missing data points. Results of such mixed models have been shown to give very similar results to multiple imputations and to be superior to completed case or last-observation-carried-forward methods of coping with missing data. 37, 38 The same model was used to examine the secondary outcome of the effect of galantamine versus placebo on the SANS total score. The primary cognitive outcome measure was a composite measure composed of 2 MCCB subtests, the Brief Assessment of Cognition in Schizophrenia (BACS) Symbol Digit test and the Hopkins Verbal Learning Test (HVLT), and the RVIP test. These measures were selected based on previous studies with nicotinic agents, which suggest that these agents should have their maximum effect on memory and attention measures. We used the formula:
))/(2n), to estimate the effect size, E, for the galantamine-placebo comparison. We used prior data to estimate the correlation between baseline and week 6 z scores for each of the 3 components of the primary cognitive outcome (r = 0.6) and to calculate the average correlation across all 3 measures (r 0 = 0.77). 39 We assumed a group size of 40 participants per group based on the sample size analysis for the negative symptom outcome. In the context of these assumptions, E = 0.65 z-score units.
In the primary analysis for cognition, the cognitive composite measure was the mean of BACS Symbol Digit test, HVLT, and RVIP test z scores, with the z scores for each test = (individual participant score − pooled baseline mean)/(pooled baseline SD). Analysis of covariance was used to estimate treatment differences on the mean of the test z scores at week 6, adjusting for the baseline mean of the z scores. The same model was used to examine the secondary outcome of the effect of oxytocin versus placebo on the cognitive composite score. An ANCOVA model was used to examine treatment group differences for the secondary cognitive outcomes: MCCB composite and domain scores and UPSA-2 total score. The covariate for these analyses was the baseline score.
The MM-ANCOVA model used for the primary negative symptom outcome was used for analyses of other symptom measures. Because the purpose of these analyses was to confirm that observed negative symptom changes were not secondary to changes in other symptom measures, we included all 3 groups in the "treatment" term and conducted follow-up analyses only if the overall treatment Â week term was significant.
For each SEC item, Fisher exact test was used to compare the number of participants who had new or worsened (compared with baseline) adverse effect severity. The Wilcoxon rank sum test for differences in change scores was used to compare treatments on SAS total score; the Mantel-Haenszel test for difference in change score was used to compare treatments on AIMS and BAS total scores. 40 Analysis of covariance was used to examine mean changes in laboratory measures and vital signs.
RESULTS
The study was conducted between March 2010 and January 2014. Eighty-six participants consented; of these, 26 did not meet inclusion/exclusion criteria, and 2 withdrew prior to randomization (see Supplemental Figure 1 : CONSORT flowchart, Supplemental Digital Content 1, http://links.lww.com/JCP/A444). Fiftyeight were randomized, of whom 2 (1 assigned to oxytocin, 1 to placebo) withdrew prior to receipt of study medication. Six of the remaining 56 participants withdrew prior to the end of study treatment: 2 from the galantamine group, 1 from the oxytocin group, and 3 from the placebo group. Three of these participants withdrew prior to the collection of any efficacy data, which left 53 for whom at least some efficacy data were obtained and 50 who completed the entire trial. Demographic and baseline clinical characteristics are presented in Table 1 .
Negative Symptoms
In the oxytocin versus placebo comparison, the MM-ANCOVA treatment Â week interaction was not significant (F 2,47.4 = 0.19, P = 0.83). The oxytocin versus placebo week 6 SANS total score comparison was also not statistically significant (Cohen d = −0.10; estimated mean difference in total scores ± SE, −1.02 ± 1.55; t 46.9 = −0.66, P = 0.51). In the galantamine versus placebo comparison, the MM-ANCOVA treatment Â week interaction was not significant (F 2,52.5 = 0.41, P = 0.67), nor was the week 6 galantamine versus placebo contrast (Cohen d = −0.15; estimated mean difference in total scores ± SE, −1.45 ± 1.39; t 46.9 = −1.04, P = 0.30) ( Table 2) .
Cognition
In the primary outcome analysis, the ANCOVA estimate of the week 6 galantamine versus placebo difference in the composite z score was 0.11 ± 0.15 (t 40 = 0.71, P = 0.48). In the oxytocin versus placebo comparison, the ANCOVA estimate of the week 6 group difference in the composite z score was 0.08 ± 0.15 (t 40 = 0.50, P = 0.62). In exploratory analyses, there were no significant galantamine/placebo or oxytocin/placebo group differences for any of the individual measure that comprised the composite measure (see Supplemental Table 1 , Supplemental Digital Content 2, http://links.lww.com/JCP/A445) ( Table 3 ).
In the analyses of the secondary cognition outcome measure: MCCB composite score (see Supplementary Table 2 In the pairwise comparisons of the individual MCCB domains, only 1 domain was nominally significant (unadjusted P < 0.05), which was not strong enough to survive adjustment for multiple comparisons (see Supplemental  Table 2 , Supplemental Digital Content 3, http://links.lww.com/ JCP/A446). There were also no significant group differences in the UPSA-2 total score: galantamine versus placebo: t 44 = −0.69, P = 0.49; and oxytocin versus placebo: t 44 = 1.25, P = 0.22 (see Supplemental Table 3 , Supplemental Digital Content 4, http:// links.lww.com/JCP/A447).
Other Symptoms
The MM-ANCOVA treatment Â week interaction for BPRS total score was as follows: F 4,82.2 = 0.46, P = 0.77; for BPRS positive symptoms was as follows: F 4,83.4 = 0.44, P = 0.78; and for CDS total score was as follows: F 4,82.5 = 1.02, P = 0.40. In addition, none of the study participants had a CDS suicide item score Participants on polypharmacy are included in the total number of users reported for each medication. One participant assigned to galantamine used both risperidone and olanzapine, and 2 used both risperidone and clozapine; 1 participant assigned to oxytocin used both haloperidol and olanzapine, 1 used both risperidone and quetiapine, and 1 used both risperidone and clozapine; 1 participant assigned to placebo used both haloperidol and clozapine, and 2 used both risperidone and clozapine. Analysis-of-covariance estimate of treatment differences on z scores at week 6, adjusted for baseline values of the corresponding z score: galantamine versus placebo: 0.11 ± 0.15, t 40 = 0.71, P = 0.48; oxytocin versus placebo: 0.08 ± 0.15, t 40 = 0.50, P = 0.62. *Composite cognitive primary outcome = mean of z scores from BACS Symbol Digit t score, HVLT t score, and RVIP test z score. greater than 1 (mild) at any visit, and only 4 of 56 participants had a rating of 1 at 1 or more visits. There were also no significant group differences in the CGI Severity of Illness item (data available upon request from the authors) (see Supplemental Table 4 , Supplemental Digital Content 5, http://links.lww.com/JCP/A448).
Plasma Oxytocin Levels
After adjustment for baseline oxytocin levels, there were no significant week 6 group differences in oxytocin levels (F 2,36 = 0.42, P = 0.66) ( Table 4) .
Adverse Effects
One study participant assigned to galantamine was hospitalized for several days, presenting with shortness of breath and suspected pneumonia, and was also treated for a urinary tract infection during the hospitalization. The serious adverse event was judged to not be related to study medication. Only 1 SEC adverse effect was significantly different among treatment groups: new onset or worsening of enuresis was reported by 1 of 20 participants assigned to galantamine, 4 of 16 participants assigned to oxytocin, and none of the 20 participants assigned to placebo (Fisher exact test, P = 0.028). There were no statistically significant treatment group differences in the SAS, AIMS, or BAS total scores (data available upon request from the authors). There were no trends toward QTc prolongation in the active treatment groups, and no participants had excessive prolongation (QTc >500 milliseconds). There were no significant group differences in vital sign changes (data available upon request from the authors). On 21 blood chemistry measurements, pairwise treatment comparisons with placebo, using analysis of covariance, suggested possible treatment effects (for potassium, triglycerides, very low-density lipoprotein, and glucose; data available upon request from the authors). However, only 2 of these comparisons (galantamine vs placebo: triglycerides; oxytocin vs placebo: glucose) had P < 0.05, unadjusted for the 42 pairwise comparisons performed. Notably, in both cases, the active treatment group exhibited a shift in the healthier direction (Table 5) .
DISCUSSION
In contrast to our study hypotheses, we found no evidence for the efficacy of intranasal oxytocin for negative symptoms or galantamine for cognitive impairments; nor was galantamine superior to placebo for negative symptoms or oxytocin superior to placebo for cognitive impairments. In addition, there was no effect of either medication on any of the other cognitive or symptom measures.
The lack of an efficacy signal for either compound precluded our ability to test whether pharmacological treatment pathways for negative symptoms and cognitive impairments overlap or are independent. The most rigorous test of this hypothesis would be to examine the comparative efficacy of known effective medications for these domains. Unfortunately, despite years of drug development, there are no known effective pharmacological agents for either of these illness components.
Our study is one of multiple studies, which has examined the efficacy of multidose intranasal oxytocin for schizophrenia. In contrast to single-dose studies, which found oxytocin benefits for social cognition in people with schizophrenia [41] [42] [43] [44] [45] [46] (but see Horta de Macedo et al 47 ), there is less clear-cut evidence to support the efficacy of repeated intranasal oxytocin administration in this population. In 2 small sample pilot projects, oxytocin was observed to improve Positive and Negative Syndrome Scale total score 48, 49 ; Feifel and colleagues 48 also found significant oxytocin effects for positive and negative symptoms. In a third study, there was a significant oxytocin effect for negative symptoms in inpatients, but not in outpatients, with schizophrenia. 50 In contrast, 2 studies, which combined oxytocin with social cognition training, failed to find any significant benefit of oxytocin for positive or negative symptoms. 51, 52 There are a number of possible explanations for the lack of negative symptom efficacy. In addition to the simple conclusion that oxytocin is not effective for these symptoms, our knowledge Analysis-of-covariance tests for treatment effects on week 6 oxytocin levels, adjusted for baseline oxytocin: F 2,36 = 0.42, P = 0.66. of the pharmacodynamics, pharmacokinetics, and optimal dosing strategy for oxytocin may be inadequate. 53, 54 Our selected dose was based on the dosage used in single-dose-challenge studies with control subjects. [6] [7] [8] [9] [10] [11] These studies suggested that the central nervous system effects of oxytocin, despite its short half-life, persist up to 2 hours. However, there is little information on how best to translate the dose used in these studies to either the dose or the frequency of administration in a multidose clinical trial. Second, in the previous multidose studies, Feifel and colleagues 48 used an intranasal oxytocin of 40 IU twice a day, whereas Lee and colleagues 50 used a dose of 20 IU twice a day, and the other 3 studies used a dose of 24 IU twice a day. 49, 51, 52 Because the most pronounced clinical effects were observed with the highest dose, perhaps our use of a lower dose contributed to the lack of observed effect. A third issue relates to the intranasal route of oxytocin administration. Despite our attempts to educate participants on the use of the nasal spray dispenser, they may have had difficulty in the proper administration of oxytocin. The multiple observations of functional and behavioral effects from single-dose intranasal challenge studies, in which the administration of oxytocin was directly monitored, [6] [7] [8] [9] [10] [11] 55 and the evidence of efficacy in inpatients, but not in outpatients, 50 provide indirect evidence to support this proposition.
In contrast to our earlier galantamine study, 17 we did not find a significant effect of galantamine for cognitive impairments. This failure to replicate may have been related to either the markedly smaller sample size in the current study and/or the shorter duration of exposure. Because galantamine does not act selectively through positive allosteric modulation of the α4β2 and α7 nicotinic receptors, it may not have been an optimal choice to test the potential utility of the α7 nicotinic receptor target. However, other recent studies with α7 nicotinic receptor partial agonists or agonists have failed to demonstrate efficacy for cognitive impairments. 56, 57 Although these results are discouraging for the α7 nicotinic receptor target, no studies have examined the efficacy of a pure positive allosteric modulator of this receptor.
The major study limitation involves the relatively small number of participants, which limits the power to detect an efficacy signal. However, we failed to find even statistically uncorrected evidence of efficacy for any of our primary or secondary end points. A larger sample would make the negative results more compelling, but additional cases would not support the efficacy hypotheses unless results were remarkably different from those observed in this clinical trial.
In summary, in the context of the limitations of this clinical trial, the efficacy hypotheses for oxytocin and negative symptoms and for galantamine and cognitive impairments were not supported.
